PGE 2 production. The early, constitutive presence of PGE 2 signi¯cantly reduced astrocyteproduced TNF-, while delayed administration had no e®ect. Finally, MSC-produced PGE 2 was not only capable of modulating in°ammation, but appeared to have an additional role in stimulating astrocyte neurotrophin production. Overall, these results support the enhanced bene¯t of encapsulated MSC treatment, both in modulating the in°ammatory response and providing neuroprotection.
Astroglia are well known for their role in propagating secondary injury following brain trauma. Modulation of this injury cascade, including in°ammation, is essential to repair and recovery. Mesenchymal stromal cells (MSCs) have been demonstrated as trophic mediators in several models of secondary CNS injury, however, there has been varied success with the use of direct implantation due to a failure to persist at the injury site. To achieve sustained therapeutic bene¯t, we have encapsulated MSCs in alginate microspheres and evaluated the ability of these encapsulated MSCs to attenuate neuro-in°ammation. In this study, astroglial cultures were administered lipopolysaccharide (LPS) to induce in°ammation and immediately co-cultured with encapsulated or monolayer human MSCs. Cultures were assayed for the pro-in°ammatory cytokine tumor necrosis factor alpha (TNF-Þ produced by astroglia, MSC-produced prostaglandin E 2 , and expression of neurotrophin-associated genes. We found that encapsulated MSCs significantly reduced TNF-produced by LPS-stimulated astrocytes more e®ectively than monolayer MSCs, and this enhanced bene¯t commences earlier than that of monolayer MSCs. Furthermore, in support of previous¯ndings, encapsulated MSCs constitutively produced high levels of PGE 2 , while monolayer MSCs required the presence of in°ammatory stimuli to induce
Introduction
Astrocytes and microglia are well known for their role in the secondary injury cascade following traumatic brain injury (TBI). In the uninjured central nervous system (CNS), these cells are responsible for homeostasis, as well as carrying out protective and developmental functions. In response to injury or stimuli, however, astrocytes and microglia take on a \reactive" phenotype. Though this phenotypic switch is initially aimed at neuroprotection and creation of a barrier between the injury and surrounding tissue, chronic cell reactivity propagates further damage and creates an environment inhibitory to neuron survival and regeneration. 1, 2 Neuroin-°a mmation, one of the most damaging chronic injury mechanisms following TBI, is primarily mediated by these reactive astrocytes and microglia through increased secretion of pro-in°ammatory cytokines that propagate further reactivity and activate the in-°a mmatory and immune responses. 3, 4 Mesenchymal stromal cells (MSCs) as a therapeutic have been demonstrated as trophic mediators in several models of CNS injury and neuroin-°a mmation, both in vitro 5, 6 and in vivo, 7, 8 and in particular, to target astroglial-mediated in°ammation. 9, 10 Despite these promising results, there has been varied success with the use of direct implantation of cells for treatment of chronic and prolonged injury mechanisms, as a result of their failure to localize and persist at the injury site, 11, 12 and their ability to migrate to other tissues. 13, 14 To control long-term e®ects and localization, we have previously developed and characterized a method to encapsulate MSCs within alginate microspheres, 15 in order to achieve sustained therapeutic bene¯t by immobilizing MSCs at the injury site and limiting their exposure to the cytotoxic injury environment.
These encapsulated MSCs signi¯cantly increased the number of anti-in°ammatory macrophages in a spinal cord injury model, 7 and modulated the in°ammatory response in organotypic hippocampal slice culture (OHSC) 16 more e®ectively than monolayer MSCs. In the latter study, prostaglandin E 2 (PGE 2 Þ was identi¯ed as a key mediator of MSC-mediated in°ammatory modulation. Here, we have expanded on that particular study, isolating the cellular components of OHSC to identify the speci¯c cellular targets of MSC anti-in°ammatory bene¯t. We also further investigated the mechanisms of PGE 2 -mediated in°ammatory modulation. Additionally, because PGE 2 is a pleiotropic molecule that has also been demonstrated to stimulate neurotrophin production, [17] [18] [19] we sought to determine if MSC and/or PGE 2 treatment might have neuroprotective, as well as anti-in°ammatory, e®ects.
In this study, we demonstrated that encapsulated MSCs signi¯cantly reduced TNF-produced by lipopolysaccharide (LPS)-stimulated astrocytes, more e®ectively than monolayer MSCs. However, LPS and MSC treatment had no signi¯cant e®ect on microglia. We further characterized the response of LPS-stimulated astrocytes to MSC treatment and found that the enhanced bene¯t of encapsulated MSCs begins early and is maintained over time. Additionally, we con¯rmed previous¯ndings that encapsulated MSCs constitutively produce high levels of PGE 2 , and that monolayer MSCs require the presence of in°ammatory stimuli to induce PGE 2 production. We have also shown that, while the early presence of PGE 2 signi¯cantly reduces astrocyte-produced TNF-, delayed administration has no e®ect. Finally, we determined the receptor subtype binding through which exogenous and MSC-produced PGE 2 are modulating in°ammation, and we demonstrated the additional role of PGE 2 in stimulating astrocyte neurotrophin production. Taken together, these results support the enhanced bene¯t of encapsulated MSC treatment, both in modulating the in°ammatory response and providing neuroprotection.
Materials and Methods

Primary cell culture
All animal procedures were approved by the Rutgers University Institutional Animal Care and Use Committee (Piscataway, NJ). Primary rat cortical astrocyte cultures were prepared according to established methods. 20 Brie°y, Sprague-Dawley rat pups (Taconic Biosciences Inc., Rensselaer, NY) at postnatal day 2-3 were decapitated, the brain rapidly removed, and placed in a dish of ice cold Hank's Balanced Salt Solution (HBSS) (Sigma-Aldrich, St. Louis, MO). Cerebral cortices were isolated, cut into small pieces after removal of the meninges, and incubated in Gey's Balanced Salt Solution (GBSS) þ 0.25% Trypsin-EDTA (Sigma-Aldrich, St. Louis, MO) for 20 min in a 37 C water bath. After 20 min, the tissue suspension was triturated and Dulbecco's Modi¯ed Eagle Medium (DMEM) (Sigma-Aldrich, St. Louis, MO) containing 10% Fetal Bovine Serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) was added to stop trypsinization. The cells were pelleted at 1200 rpm for¯ve min, resuspended in DMEM containing 10% FBS, 100 units/ml penicillin and 100 g/ml streptomycin (Life Technologies, Carlsbad, CA) (\maintenance medium"), and¯ltered through a cell strainer. The¯nal suspension was cultured in 75 cm 2°a sks (one°ask per cortex), and incubated at 37 C in 5% CO 2 . For astrocyte culture, cells were passaged at con°uency (5-7 days) and used for experiments at passage one to two. For glial cultures, cells were cultured for 7-10 days, with media exchanged every 2-3 days. To isolate microglia, cultures were shaken at 180 rpm for two hours. The cells in suspension were removed and plated for experiments. Both astrocytes and microglia were plated in 24-well plates (5 Â 10 4 cells/well) two days prior to experiments.
Human MSC culture
Human bone-marrow mesenchymal stromal cells from a single donor (male, 28 years) were purchased from Texas A&M at passage one and cultured as previously described. 21 Brie°y, MSCs were cultured in Minimum Essential Medium alpha (MEM-Þ without ribo-and deoxyribo-nucleosides (Life Technologies, Carlsbad, CA), supplemented with 10% FBS (Atlanta Biologicals, Lawrenceville, GA), 1 ng/ml basic¯broblast growth factor (Peprotech, Rocky Hill, NJ), 100 units/ml penicillin, and 100 g/ml streptomycin (Life Technologies, Carlsbad, CA). Cells were plated at 5,000 cells per cm 2 and allowed to proliferate to 70% con°uence (approximately 4-5 days) before passaging. Only MSCs at passages two through¯ve were used to initiate subsequent experiments. Monolayer cultures of MSCs, used as controls in all experiments, were seeded one day prior to use in transwells at 2:5 Â 10 4 , 5 Â 10 4 , or 1 Â 10 5 cells/well. All cultures were incubated at 37 C in 5% CO 2 .
Alginate microencapsulation
Alginate poly-L-lysine microencapsulation of MSCs was performed as previously described. 15 A 2.2% (w/v) alginate solution (MW: 100,000-200,000 g/ mol, G-content 65-70%, Sigma-Aldrich, St. Louis, MO) was generated with Ca 2þ -free DMEM (Life Technologies, Carlsbad, CA). Cultured MSCs were dissociated and resuspended in 2.2% alginate to yield a¯nal solution of 4 Â 10 6 cells/ml in 2% ðw=vÞ alginate (resulting in approximately 150 cells/capsule), that has been previously determined to maintain MSC viability and an undi®erentiated state. 7 The cell suspension was transferred to a syringe pump (KD Scienti¯c, Holliston, MA), set at a°ow rate of 10 mL/h. Alginate beads were generated using an electrostatic bead generator (Nisco, Zurich, Switzerland) with accelerating electrode at an applied voltage of 6.4 kV. The resulting bead diameter was 500 AE 50 m. The beads were extruded into a bath of CaCl 2 (100 mM) (Sigma-Aldrich, St. Louis, MO) containing 145 mM NaCl (Sigma-Aldrich, St. Louis, MO) and 10 mM MOPS (Sigma-Aldrich, St. Louis, MO). Microencapsulated cells were washed once with phosphate bu®ered saline (PBS) (Sigma-Aldrich, St. Louis, MO) and then treated for two minutes with poly-L-lysine (Sigma-Aldrich, St. Louis, MO, MW: 68,600 g/mol) (0.05% w=v), followed by an additional PBS wash. The microencapsulated cells were resuspended in 5 ml MEM-(Life Technologies, Carlsbad, CA) and transferred to a 25 cm 2 tissue culture°ask, maintained in an upright position. Encapsulated cells were incubated at 37 C in 5% CO 2 and used for experiments one day post-encapsulation. To determine average number of cells per capsule for dosing purposes, 15 l of capsules were added to 200 l of 1% EDTA. Capsules were immediately counted in this volume ðn ¼ 3Þ, and the average number of capsules/ml was calculated accordingly. The capsule þ EDTA solutions were incubated at room temperature for¯ve minutes to allow lysis of the alginate and release of MSC from capsules. A 10 l volume of these cell suspensions was counted on a hemacytometer to determine the average number of cells/ml ðn ¼ 3Þ. The average number of cells/capsule was calculated as (cells/ml)/ (capsules/ml), and used to determine the number of capsules necessary for experimental treatment. Based on the number of capsules necessary to achieve the desired MSC dose, an equivalent number of capsules was chosen for empty capsule controls.
LPS injury and co-culture
Polyester membrane transwell inserts (Corning Inc. Tewksbury, MA, 6.5 mm, 0.4 m) containing monolayer or encapsulated MSCs (2:5 Â 10 4 , 5 Â 10 4 , or 1 Â 10 5 cells/transwell) were added to host cultures in 24 well plates, and maintenance medium was exchanged for DMEM þ 1% FBS, supplemented with 100 units/ml penicillin and 100 g/ml streptomycin (\low serum media") AE1 g/ml LPS (Escherichia coli 055:B5, Sigma-Aldrich, St. Louis, MO). 22, 23 Nonstimulated and stimulated host cultures without MSC co-culture were used as controls. Cultures were returned to the incubator at 37 C in 5% CO 2 for 6, 12, 24, or 48 h, after which media supernatants were collected and cells were¯xed.
PGE 2 and blocking studies
Before all experiments, astrocyte medium was exchanged for low serum media AE1 g/mL LPS. For exogenous PGE 2 treatment, human PGE 2 (Cayman Chemical, Ann Arbor, MI) at 1, 2, 4, 8, 16, or 20 ng/mL was added immediately, or 6 h after LPS. For agonist studies, iloprost (EP1, Cayman Chemical, Ann Arbor, MI), butaprost (EP2, Cayman Chemical, Ann Arbor, MI), sulprostone (EP3, Cayman Chemical, Ann Arbor, MI), or CAY10598 (EP4, Cayman Chemical, Ann Arbor, MI) was added at 10 nM, 100 nM, 1 M, or 10 M. For antagonist studies, 20 ng/mL PGE 2 was added along with SC-51322 (EP1, Cayman Chemical, Ann Arbor, MI), PF-04418948 (EP2, Cayman Chemical, Ann Arbor, MI), L-798,106 (EP3, Sigma-Aldrich, St. Louis, MO), or L161,982 (EP4, Cayman Chemical, Ann Arbor, MI) at 10 nM, 100 nM, 1 M, or 10 M. For antagonist blocking studies, monolayer or encapsulated MSCs were co-cultured with astrocytes, and antagonists were added concurrently at doses determined by antagonist studies (10 M SC-51322, 10 M PF-04418948, 10 M L-798,106, or 1 M L-161,982). All cultures were returned to incubators at 37 C in 5% CO 2 , and media supernatants were collected 24 h post-LPS stimulation.
Cytokine measurement
At the end of each treatment, cell culture media supernatants were collected and stored at À20 C. Media supernatants were assayed for TNF-produced by astrocytes or microglia using a rat TNF-ELISA (Biolegend, San Diego, CA) according to the manufacturer's instructions. Total PGE 2 secretion ðrat þ humanÞ was evaluated using Prostaglandin E 2 EIA (Cayman Chemical, Ann Arbor, MI), according to the manufacturer's instructions.
PCR array
For the analysis of astrocyte neurotrophin and neurotrophin receptor expression after LPS, LPS þ monolayer MSC, LPS þ encapsulated MSC, and LPS þ 20 ng/ml PGE 2 treatments, experiments were carried out as described above. After 24 h, medium was collected and assayed for TNF-as described above. Cells were washed once with PBS, then dissociated with 0.25% Trypsin-EDTA (Sigma-Aldrich, St. Louis, MO) for¯ve minutes, after which trypsin was neutralized with astrocyte maintenance medium. The cells were harvested and samples pooled per condition then spun down and resuspended in PBS. Cells were again centrifuged, and the PBS supernatants were removed. Pellets were°ash frozen on liquid nitrogen and stored at À80 C. RNA isolation and RT-PCR were performed by Qiagen (Frederick, MD) using manufacturer-speci¯c kits and a rat neurotrophin and neurotrophin receptor array (RT 2 Pro¯ler PCR Array, Cat. # PARN 031Z). Fold change/regulation was calculated using the ÁÁC T method, in which ÁC T is calculated between the gene of interest (GOI) and an average of reference genes (HKG), followed by ÁÁC T calculations (ÁC T (Test Group) À ÁC T (Control Group)). Fold Change was then calculated using 2^ðÀÁÁC T Þ formula. Nonsupervised hierarchical cluster analysis of the entire dataset was generated using the Qiagen data analysis web portal (http://www.qiagen.com/geneglobe). 
Statistical analysis
All results are expressed as a mean AE standard error (S.E.). All data presented are averaged from ! 3 separate experiments, each with N ¼ 2-3 independent replicates. PCR array data are obtained from one experiment, with n ¼ 6 cultures per condition, and samples pooled per condition. Kaleida Graph (Synergy Software, Reading, PA) was used for statistical evaluation. Comparisons between di®erent conditions were performed using one-way ANOVA followed by post-hoc Tukey-HSD test, with statistical signi¯cance determined at p 0:05.
Results
MSCs attenuate production of pro-in°ammatory TNF-® in LPS-stimulated astrocytes
The bacterial endotoxin lipopolysaccharide (LPS) is known to induce in°ammation through activation of the immune response and stimulation of cytokine production, and has been commonly used to model the neuroin°ammatory component of secondary CNS injury both in vitro 24, 25 and in vivo. 26, 27 To evaluate the ability of MSC treatment to attenuate the astroglial in°ammatory response, we stimulated astrocyte or microglial cultures with 1 g/ml LPS and concurrently treated with monolayer or encapsulated MSCs for 24 h, after which cell culture media was assayed for the pro-in°ammatory cytokine TNF-produced by the host cultures. In astrocyte culture, LPS induced a signi¯cant increase in TNF-, and both monolayer and encapsulated MSCs signi¯cantly reduced TNFproduction at all doses, [ Fig. 1(a) ]. Additionally, at 1 Â 10 5 cells/well, encapsulated MSCs had a sig-ni¯cantly greater e®ect on reducing TNF-as compared to the same dose of monolayer MSCs. Empty capsule treatment had no signi¯cant e®ect on TNF-reduction in astrocytes. In microglia, however, LPS did not cause a signi¯cant increase in TNF-production over control cultures, and neither monolayer nor encapsulated MSC treatment resulted in signi¯cant changes in TNF-[ Fig. 1(b) ].
Encapsulated
MSCs are more e®ective than monolayer in reducing TNF-®, and exhibit increased PGE 2 production
Having identi¯ed astrocytes as a target of MSC treatment for neuroin°ammation, we then further characterized the treatment response over time. Astrocyte cultures were administered 1 g/ml LPS and treated with monolayer or encapsulated MSCs (1 Â 10 5 cells/transwell), and cell culture media was collected at 6, 12, 24, and 48 h. Rat TNF-and total PGE 2 were evaluated by ELISA and EIA, respectively. We found that TNF-production by Fig. 2(a) ]. All data are normalized to untreated, LPS-stimulated astrocytes at 24 h post-stimulation. PGE 2 is a critical component of the early in-°a mmatory response, and we have previously identi¯ed PGE 2 as a key mediator of MSC-mediated in°ammatory modulation in macrophage. 7 and organotypic hippocampal slice cultures. 16 Here, we have shown that while both monolayer and encapsulated MSCs produce increased PGE 2 in response to in°ammatory stimuli, encapsulated MSCs produce signi¯cantly higher levels at all time points, and begin production earlier than monolayer MSCs (6 h versus 12 h post-stimulation) [ Fig. 2(b) ].
Early presence of PGE 2 bene¯ts in°ammatory modulation
Given the enhanced anti-in°ammatory bene¯t of encapsulated MSCs, and the high levels of PGE 2 they produce from early time points post-LPS stimulation, as well as previous data correlating increased PGE 2 with decreased TNF-, 16 we sought to determine if the early PGE 2 presence, as seen with encapsulated MSC treatment, bene¯ts in°ammatory modulation. To achieve this, we added exogenous human PGE 2 to LPS-stimulated astrocyte cultures at the time of LPS administration or 6 h after and evaluated culture media for rat TNF-secretion 24 h post-LPS stimulation. There is a doseresponse e®ect of increasing human PGE 2 on reducing TNF-when immediately administered (0 h), but no signi¯cant reduction of TNF-by any PGE 2 dose when administered 6 h post-stimulation ( Fig. 3 ).
PGE 2 reduces TNF-® through speci¯c prostaglandin receptor subtypes
Although PGE 2 has been previously recognized for its pro-in°ammatory actions, 28, 29 recent studies provide evidence that PGE 2 acts as an anti-in-°a mmatory mediator dependent on receptor subtype binding and a±nity, as well as local PGE 2 concentration. 30 To determine the prostaglandin subtypes involved in reducing astrocyte-produced TNF-, we¯rst used agonists speci¯c for each of the four receptor subtypes -EP1 (iloprost), EP2 (butaprost), EP3 (sulprostone), and EP4 (CAY10598). Astrocyte cultures were administered 1 g/ml LPS AE receptor agonists, and cell culture media was collected at 24 h. Using ELISA for rat TNF-, we found that the EP2 and EP4 receptors are highly involved in reducing TNF-, and the Fig. 4(a) ], though this may be an e®ect of relative receptor subtype expression by astrocytes.
The EP3 receptor is not involved in reducing TNF-in our culture model. Again, this may due to lack of EP3 expression by astrocytes, which was not evaluated. A range of doses was evaluated, but only the most e®ective dose (10 M) is represented in the¯gure.
To con¯rm these¯ndings, we then evaluated antagonist blocking of PGE 2 in°ammatory mediation for each receptor subtype -EP1 (SC-51322), EP2 (PF-04418948), EP3 (L-798,106), and EP4 (L-161,982). Astrocyte cultures were administered 1 g/ml LPS þ 20 ng/ml PGE 2 AE receptor antagonists for 24 h, after which cell culture media was assayed by TNF-ELISA. Again, we found the EP1, EP2, and EP4 to be signi¯cant targets of antagonist blocking [ Fig. 4(b) ]. In contrast to the agonist study, EP3 appears to be a target of antagonist blocking at the highest dose evaluated, but this could potentially be due to non-speci¯c binding to other receptor subtypes.
Having determined e®ective doses for antagonist blocking of PGE 2 -mediated in°ammatory modulation, and the receptor subtype targets, we then carried out EP receptor antagonist blocking of MSC treatment, to determine through which receptor subtype(s) MSC-produced PGE 2 is modulating TNF-production. Astrocyte cultures were administered 1 g/ml LPS and treated with monolayer or encapsulated MSCs (1 Â 10 5 cells/ transwell) AE receptor antagonists, and cell culture media was collected after 24 h for evaluation by TNF-ELISA. Signi¯cant blocking of the MSC-mediated TNF-reduction is achieved with Prostaglandin E 2 Produced by Alginate-Encapsulated Mesenchymal Stromal Cells EP1, EP2, and EP4 receptor antagonists, but as with the agonist study, no e®ect is seen when targeting the EP3 receptor ( Fig. 5 ). Hence, it appears MSC-produced PGE 2 is anti-in°ammatory via binding to the EP1, EP2, and EP4 receptors.
Comparative responses of LPS-stimulated astrocytes to MSC and PGE 2
MSC appeared to reduce the in°ammatory response via the secretion of PGE 2 . Of course, PGE 2 , is just one of many molecules secreted by MSC, and MSC and PGE 2 a®ect other aspects of cell behavior. For example, although PGE 2 is best known for its role in the in°ammatory response, several studies have demonstrated additional downstream e®ects in stimulating expression and/or production of neurotrophic factors [17] [18] [19] as well as neuroprotective e®ects. [31] [32] [33] Given the potential for broader responses to these two therapies, as well as di®erences between free and encapsulated MSC, we preliminarily screened gene expression by astrocytes of a number of factors that may contribute to the neuroprotective and/or regenerative environment following TBI. We were particularly interested in identifying similarities and di®erences in the expression pro¯les of astrocytes induced to an in°ammatory state with LPS that were treated with PGE 2 or with MSC. Astrocyte cultures were administered 1 g/ml LPS and concurrently treated with monolayer or encapsulated MSCs (1 Â 10 5 cells/transwell), or 20 ng/ml PGE 2 for 24 h. Separate astrocyte cultures were not stimulated with LPS and were left untreated. After 24 h, astrocytes were harvested for RNA isolation and analysis by PCR array for expression of 84 neurotrophin, neurotrophin receptor, and neurotrophin-associated genes. Separate TNFlevels in these cultures were consistent with results shown in Figs. 1 and 2 , indicating that the cultures were representative of the typical response. Fold changes in expression relative to unstimulated, untreated astrocytes are shown in Supplemental  Table 1 . To compare the responses in the therapeutic conditions, the data for LPS-stimulated astrocytes treated with free MSC, encapsulated MSC, and PGE 2 were normalized to the response of untreated, LPS-stimulated astrocytes (Fig. 6 ). For 30 genes, a greater than two-fold change in expression was observed for at least one condition, and for six of these 30 genes, fold changes induced by encapsulated MSC treatments paralleled those observed with PGE 2 treatment. These preliminary but encouraging trends suggest that increased PGE 2 production by encapsulated MSCs may confer an enhanced neuroprotective e®ect over monolayer MSCs.
Discussion
The traditional \neurocentric" approach to developing therapies for TBI has focused on regenerating neurons and repairing synapses at the injury site. However, it is important to consider all cell types present that contribute to the ongoing cell death, degeneration, and inhibition of regeneration. Astrocytes exhibit distinct responses to brain injury, and are a key player in several components of secondary injury including in°ammation, 23, 34 excitotoxicity, 35 and free radical-mediated injury. 36, 37 Here, we focus on the role of these cells in mediating the neuroin°ammatory component of secondary injury. Rapidly after insult, astrocytes release several pro-in°ammatory cytokinesincluding TNF-, IL-6, IFN-and IL-1.
These cytokines are responsible for signaling inltration of other in°ammatory mediators to the injury site and stimulating production of additional cytokines, 38 thus continually amplifying the in-°a mmatory response. This chronic perpetuation of neuroin°ammation by astrocytes, as well as their reaction to other TBI-related insults, signi¯cantly contributes to the prolonged cascade of injury, and is linked to neuronal cell death and degradation. 39, 40 Several studies have demonstrated the therapeutic potential of MSCs to target multiple components of the secondary injury cascade following TBI, including neuroin°ammation 9,41,42 -speci¯cally, through modulation of the tissue and cellular environment. 43 Direct delivery of cells, however, presents limitations to long-term bene¯ts and clinical translation due to lack of persistence at the injury site and a decrease in cell number at the site over time. 11, 44, 45 Additionally, it has been demonstrated that intravenously administered MSCs migrate to nontarget tissues, including the liver, spleen, kidney, and lungs, even up to one year after treatment. 14, 46 To overcome these limitations, we have immobilized MSCs in alginate microspheres, which have been shown to persist in the brain up to six months. 47 Our previous studies have used alginate microencapsulation of MSCs to deliver cells after spinal cord injury (SCI). These encapsulated MSCs promoted the anti-in°ammatory M2 macrophage phenotype, in both in vitro macrophage culture and an in vivo model of SCI, and reduced levels of pro-in°ammatory TNF-and the activation marker inducible nitric oxide synthase (iNOS) when co-cultured with LPS-stimulated macrophages. 7 The treatments were delivered 24 h after spinal cord injury, which suggests a long therapeutic window.
In previous studies, we further explored the mechanism by which encapsulated MSCs alleviate CNS in°ammation and pathology using an OHSC model of in°ammation. We found that encapsulated MSCs conferred enhanced in°ammatory modulation, compared to monolayer MSCs, and identi¯ed PGE 2 as a primary mediator in attenuating the in°ammatory response. 16 This is consistent with report that MSC-secreted PGE 2 is an important mediator of in°ammation, 6 and that 3D aggregates of MSCs (spheroid culture) display enhanced PGE 2 production and anti-in°ammatory properties. 48, 49 Following these results, we herein aimed to identify and distinguish cell-speci¯c responses to in°ammation and MSC therapy -speci¯cally, the role of astroglial cellsand to further elucidate the mechanism(s) underlying the improved e±cacy of encapsulated MSCs. Our results highlight the contribution of astrocytes to the neuroin°ammatory Prostaglandin E 2 Produced by Alginate-Encapsulated Mesenchymal Stromal Cells component of TBI, and demonstrate that astrocytes, but not microglia, are highly responsive to our encapsulated MSC treatment. As with OHSC, our ndings show that encapsulated MSC treatment results in a signi¯cantly greater reduction of TNFcompared with an equivalent dose of monolayer MSC treatment. This improved reduction of TNFcommences early after treatment (12 h) and is maintained to at least 48 h post-treatment. Previous characterization of viability and proliferation of MSCs within the alginate microcapsule reveals a far lower proliferation rate than that of monolayer MSCs, 7 which is consistent with our previous ndings with encapsulated embryonic stems cells in an alginate microenvironment. 50 Though not explored in this study, these data render it unlikely that enhanced reduction of TNF-is a result of di®erences in cell number over the culture period.
Having previously identi¯ed PGE 2 as a key MSCproduced in°ammatory mediator in macrophage 51 and OHSC 16 culture models, we continued to evaluate and characterize the role of this molecule in contributing to the enhanced bene¯t of encapsulated MSC treatment. In LPS-stimulated astrocyte culture, we found that encapsulated MSCs constitutively produce higher levels of PGE 2 than monolayer MSCs, and begin doing so at earlier time points. Together with our data demonstrating that early presence of PGE 2 signi¯cantly reduces astrocyte-produced TNF-, while delayed administration has no e®ect, these results further support the importance of PGE 2 in modulating in°ammation and the advantage of encapsulating MSCs for treatment.
Though we have shown it to have a strong anti-in°ammatory e®ect in our culture models, PGE 2 is a highly pleiotropic molecule known to be both pro- 29, 52 and anti-in°ammatory, 53, 54 and has roles in pain, [55] [56] [57] cancer, 58,59 neuroprotection, [31] [32] [33] and wound repair, 60,61 among others. 62 This diversity of functions is largely attributed to the ability of PGE 2 to bind four receptor subtypes -EP1, EP2, EP3, and EP4 30that mediate PGE 2 actions through distinct downstream signaling pathways. 63 In neurological pathology alone, PGE 2 displays signaling versatility dependent on receptor binding, afnity, and expression levelsoften with opposing actions. 64 The EP1 and EP3 receptors have been implicated in excitotoxic cell death and exacerbation of injury in models of cerebral ischemia, [65] [66] [67] while the EP2 and EP4 receptors have demonstrated neuroprotection against excitotoxic insult 68, 69 and cerebral ischemia. 32, 33, 70 In contrast to the neuroprotective e®ects in models of excitoxicity, EP2 elicits an opposing, neurotoxic response in models of neurodegeneration 71, 72 and has demonstrated con-°i cting roles in neuroin°ammation. Activation of the EP2 receptor induced neurotoxicity in LPS-stimulated OHSC 73 and microglia-neuron co-cultures, 74 but was also shown to reduce IL-1 production 75 and iNOS expression 76 by LPS-stimulated microglia. Signaling through the EP4 receptor attenuated neuroin°ammation in LPS-stimulated microglial 77 and macrophage 51 cultures, and deletion of microglial EP4 in a mouse Alzheimer's model increased in-°a mmation and A deposition. 78 Given the multitude of actions PGE 2 exhibits in CNS pathology, we sought to determine which EP receptors subtypes were involved in our observed PGE 2 -and MSC-mediated in°ammatory modulation. Though all four receptor subtypes are known to be expressed by astrocytes, 64 their contribution to the astrocyte-induced in°ammatory response, and attenuation thereof, remains relatively uncharacterized. Our data reveal anti-in°ammatory actions of exogenous and MSC-produced PGE 2 through the EP1, EP2, and EP4 receptors, corroborating previous studies describing EP2 and EP4 as anti-in°ammatory in microglial cultures. 75, 76 Not surprisingly, PGE 2 binding to EP2 and EP4 is known to activate similar downstream pathways via increased intracellular cAMP. The dichotomous roles of EP2 in the in°ammatory response, however, may be due to evidence that EP2-induced cAMP is capable of binding two separate e®ectors -PKA and Epacwhose signaling pathways mediate di®erent e®ects. 79 The role of EP1 in neuroin-°a mmation, speci¯cally, has not been thoroughly explored, but EP1 activation has been shown to propagate in°ammatory pain. 56, 80 To the best of our knowledge, this is the¯rst study to demonstrate a role of the EP1 receptor in modulating astrocytemediated in°ammation. PGE 2 and MSC treatments may a®ect a number of cellular responses in addition to their anti-in-°a mmatory e®ects, including neuroprotection 32,78 and neurotrophic factor production, 19, 81 both of which may further enhance recovery for TBI. To preliminarily evaluate similarities and di®erences between PGE 2 -and MSC-treatments following induction of in°ammation in astrocyte cultures, and to identify additional potential bene¯ts of MSC E. C. Stucky et al. encapsulation, we screened an array of the genes using PCR. The PCR array panel revealed many genes that were a®ected by all three treatments, which is consistent with PGE 2 -mediated changes. However, expression of a number of genes di®ered following the three treatments. For example, exogenous PGE 2 and encapsulated MSC treatment, but not monolayer MSCs, up-regulated astrocyte expression of the neurotrophic factors BDNF and NT-3. Additionally, cluster analysis of the entire dataset showed expression patterns to be most similar between PGE 2 and encapsulated MSC treatment conditions, suggesting that encapsulated MSC-induced changes in expression may be largely due to increased PGE 2 production. Dissimilarities between these conditions also exist, where encapsulated MSC-induced gene regulation more closely matches that of monolayer MSCs than exogenous PGE 2 . The changes previously observed in the MSC secretome in response to OHSC in°ammatory signals, 16 could point to other MSC-produced mediators responsible for astrocyte gene regulation.
In summary, our results further con¯rm that alginate encapsulation of MSCs enhances their ability to modulate in°ammation through reduction of the pro-in°ammatory cytokine TNF-, and identify astrocytes as the primary target of this treatment. We show that the improved anti-in°ammatory bene¯t of encapsulated MSCs may be due to early, constitutive production of high levels of PGE 2 , and the necessity of early PGE 2 administration to reduce in°ammation. Additionally, we determined EP receptor subtypes through which exogenous and MSC-produced PGE 2 are acting to modulate in-°a mmation, and demonstrated additional therapeutic bene¯t of encapsulated MSCs through induction of astrocyte neurotrophin expression. These results suggest that alginate encapsulation may be a novel and e®ective method to deliver MSCs for TBI treatment, and may provide sustained, multi-potent bene¯t by modulating in°ammation and providing neuroprotection through induction of neurotrophin expression. The goals of the current study were to examine the mechanisms of MSC-mediated regulation of the in°ammatory response of astrocytes, and a number of studies must be completed before clinically translating the therapy, such as identifying a therapeutic window for administering the treatment. However, previous work with encapsulated MSC following SCI demonstrated e±cacy in mitigating in°ammation when the treatment was applied 24 h after the initial trauma.
